Inhaled study drug for healthy adults and adults with asthma
Part of Immune system & allergy, Lungs & breathing clinical trials.
This early-phase study tests an inhaled medication (CHF10136) to see if it's safe and how the body handles it. It includes both healthy adults and people with asthma, and participants will be monitored closely throughout.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old (depending on the part of the study).
- You need to be in generally good health, or have mild to moderate asthma that is stable.
- Your body mass index (BMI) should be between 18 and 35, and you must weigh at least 50 kg.
- You must not have used certain asthma medications (like inhaled corticosteroids) within a specific time before the study—this depends on the part.
- You cannot have other significant lung diseases (like COPD or pulmonary fibrosis).
- You must be willing to follow study procedures and attend all visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new inhaler (CHF5993) works as well as the current standard for adults with mild to moderate asthma. It compares how well the medicine controls asthma and opens airways.
This study tests a new three-part asthma inhaler (CHF 5993) in people whose asthma isn't well-controlled even though they're already using two standard asthma medicines together. The goal is to see if adding this new medicine helps control asthma better.
This study tests a new medicine called CHF6467 given as a nasal spray. It looks at how safe the medicine is, how it is absorbed and removed from the body, and what side effects it might cause. Healthy volunteers aged 18 to 55 can take part.
This study tests an experimental medicine (PF-08103402) to see how well it is tolerated and how it acts in the body, in healthy adults and in people with mild-to-moderate asthma. Participation may help researchers learn if this treatment could help manage asthma symptoms.
This study tests a new inhaled dry powder medicine (called ICF001) in healthy volunteers to see how safe it is and what side effects it might cause. It is a first-in-human study, so participants will help researchers understand the drug's effects and how it moves through the body.
This study tests an investigational medicine called PF-07275315 for people with moderate-to-severe asthma that is not well controlled with current treatments. The goal is to see if it can reduce asthma attacks and improve breathing.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.